Abstract
For arrhythmia triggers that are secondary to dysfunctional intracellular Ca(2+) cycling, there are few, if any, agents that specifically target the Ca(2+) handling machinery. However, several candidates have been proposed in the literature. Here we review the idea that these agents or their derivatives will prove invaluable in clinical applications in the future.